Ranpak Expands its Global Footprint Through Large-Scale Sustainable Packaging Partnership with Thalia
CONCORD TOWNSHIP, Ohio & HAGEN, Germany--(BUSINESS WIRE)--Ranpak Holdings Corp. ('Ranpak') (NYSE: PACK), a global leader in sustainable packaging automation technology and solutions, today announced a strategic partnership with Thalia, the largest book retail chain in the DACH region (Germany, Austria, and Switzerland). The partnership marks a significant advancement in Thalia's fulfillment capabilities and commitment to sustainability.
As part of the first stage of this collaboration, Thalia will install at its fulfillment and production facility, that will be opened in 2026, a total of 12 Ranpak automated packaging systems, including 3 Cut'It!™ EVO, 3 Form'It!™ packers, and 6 Flap'it!™ systems.
Flap'it! – an automated right-sizing solution developed to streamline the packing process and protection for small, flat items.
Form'it! – an automated box-forming system designed to improve the first step in the packaging process by automatically erecting corrugated boxes.
Cut'it! EVO – an advanced automated right-sizing system that optimizes the height of shipping boxes after items have been picked and packed to minimize void and automatically closes and seals them – all with zero waste.
Ranpak's automation portfolio integrates seamlessly into modern fulfillment environments, allowing Thalia to optimize its packaging process across both its robust ecommerce platform and network of more than 500 brick-and-mortar stores, significantly enhancing throughput, package protection, and environmental performance.
'At Ranpak, we are committed to helping companies transition to smarter, more sustainable packaging processes,' said Omar Asali, Chairman and CEO of Ranpak. 'Our partnership with Thalia represents a shared vision for automation that not only delivers operational excellence but also reduces environmental impact. We are proud to support Thalia's fulfillment network with our innovative, paper-based automation solutions.'
This installation represents Phase One of a broader initiative, with additional Ranpak systems under consideration as Thalia scales its operations to meet increasing customer demand across its digital and retail channels.
'Partnering with Ranpak for our new omni-channel-hub, which will be an outstanding fulfillment and production facility, marks a key milestone in our mission to make book distribution smarter, greener, and more efficient,' said Marco Rebohm, Managing Director Supply Chain and Logistics at Thalia. 'These new systems will enhance our fulfillment capabilities, support our sustainability goals, and position us for scalable growth. This is just the beginning of a powerful transformation and exciting partnership ahead.'
The integration of Ranpak's solutions will be implemented by Element Logic, known for optimizing warehouse operations using AutoStore and other smart technologies.
About Ranpak
Founded in 1972, Ranpak's mission is to deliver sustainable packaging solutions that improve supply chain performance and reduce environmental impact. With a global footprint and a reputation for innovation, Ranpak helps businesses transition away from plastic packaging through its extensive line of paper-based products and advanced automation systems. For more information, visit www.ranpak.com.
About Thalia
Thalia is the market-leading omni-channel-book retailer in Germany, Austria, and Switzerland, with a turnover of 1,9 bn. Euros in FY 2023/24 and approx. 6,800 employees. More than 500 bookshops make up the Thalia store network, combined with a strong presence in eCommerce to create a unique customer experience. Thalia stands for literacy, culture, and sustainable development across the DACH region. For more information, visit unternehmen.thalia.de.
About Element Logic
Element Logic is a technology company specializing in optimizing warehouse operations through intelligent automation systems such as AutoStore. With deep expertise in logistics processes and software integration, Element Logic ensures future-ready solutions that drive efficiency and scalability for customers across Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
33 minutes ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Wire
an hour ago
- Business Wire
Scam Summer: Experts Warn Price Caps May Fuel £100 Million in Ticket Fraud
LONDON--(BUSINESS WIRE)--With the UK heading into its biggest summer of live events in years, experts are warning that the Government's plans to cap the resale price of tickets could backfire - dramatically increasing fraud, pushing fans into the hands of scammers and triggering a financial backlash for both banks and consumers. Experts warn that price caps may fuel £100 million in ticket fraud. Share While the move to strengthen regulation is welcome, the proposal to restrict the price of resold tickets is raising serious concerns. In response to the Government's recent consultation on ticket resale regulation, which includes proposals to restrict the price of resold tickets, We Fight Fraud (WFF) - supported by one of the UK's leading fintechs, Revolut - is sounding the alarm: price caps won't protect fans - they'll expose them. Data from the National Fraud Intelligence Bureau, Action Fraud and the National Crime Agency shows that the cost of reported ticket fraud for England and Wales was £70 million last year. Yet this pales into insignificance with how much consumers would lose in the event of a mooted price cap being introduced. New figures from Bradshaw Advisory, backed by independent research from We Fight Fraud, suggest that number would quadruple as ticket resales migrate from the regulated secondary market to social media. This would mean consumers being hit in the pocket to the tune of £280 million a year – with £100 million of that falling in the peak summer months alone. Dr Nicola Harding, CEO of We Fight Fraud, a specialist unit made up of ex-police, intelligence officers, cyber experts, and financial crime investigators, said: 'Capping resale prices may sound fan-friendly - but in practice, it pushes buyers into unregulated, risky spaces where criminals operate freely. We've tested this market. We've seen what happens. Price caps don't stop fraud - they multiply it and we could see live event fans defrauded to the tune of £100 million this summer.' As part of its investigation, We Fight Fraud conducted a covert ticket-buying operation at a Premier League match in March between Liverpool and Southampton. The results were stark: Three out of four tickets purchased via social media in test cases were either fake or never arrived. Two out of five tickets were outright scams. Two others were obtained illegally via hijacked memberships. Buyers were asked to pay bogus 'name change' fees and transfer money to money mule accounts. All scams were orchestrated via social media platforms and encrypted messaging apps. 'These aren't opportunistic chancers,' said Harding. 'They're organised criminal networks exploiting fans who've been shut out of safe, legitimate resale routes. 'The more you limit legitimate access, the more you push desperate fans into the shadows - and that's exactly where scammers lie in wait.' While We Fight Fraud's research* focused on the UK, international data tells a worrying story. In Ireland and Victoria, Australia - where ticket resale caps are in place - fraud has surged. Bradshaw Advisory's research found that in Ireland, 13.6% of fans reported being scammed, over three times the UK's 3.8% rate. Independent research shows fraud has risen in step with these restrictions. Since October 2024, UK banks have been required to reimburse victims of Authorised Push Payment (APP) fraud, which includes most ticket scams. With resale restrictions forcing more buyers onto risky channels, the financial burden is now spreading from fans to banks - and eventually to the wider economy. Revolut saw ticket scams increase by 40% in the run-up to Taylor Swift concerts in London in August 2024. "We know that highly anticipated events, like concerts and sports matches, can become a target for unscrupulous criminals preying on enthusiastic fans,' said Dave Eborne, Head of Fraud Operations at Revolut. 'Especially with sought-after tickets, fraudsters leverage both the fear of missing out on a unique opportunity and a sense of urgency due to scarcity and high demand. The idea that a potential ticket could disappear quickly encourages people to act fast without thinking – but it's vital that consumers look for tell-tale warning signs before handing over their hard-earned cash. As Dr. Harding's research shows, banning or capping resale doesn't stop these scams; it simply provides another platform for them to thrive, costing fans and the wider economy through increased fraud. Smart, transparent regulation of the resale market, and robust consumer education on the warning signs of ticket scams, are the only real solutions to protect fans." For further information please contact contact@ or call us on +44(0)20 3633 0996 NOTES TO EDITORS About Revolut: Revolut is one of the UK's leading fintechs, helping people get more from their money. In 2015, Revolut launched in the UK offering money transfer and exchange. Today, more than 50 million customers around the world use dozens of Revolut's innovative products to make more than half a billion transactions a month. Across our personal and business accounts, we give customers more control over their finances and connect people seamlessly across the world. We Fight Fraud ( is a testing and research consultancy that specialises in identifying vulnerabilities related to financial crime. The independent research by WFF was commissioned by viagogo. Reinforcing We Fight Fraud's findings, Lloyds Bank recently issued a warning following a surge in scams linked to Oasis reunion tickets. Their analysis revealed that over two-thirds of all ticket scams now originate on social media, with Facebook responsible for 90% of those cases. Victims lost an average of £436, contributing to an estimated £2 million in total ticket scam losses over the past year. The scams typically involved convincing but fake listings, pressure to act quickly, and bogus charges like 'admin' or 'name change' fees - tactics that mirror those uncovered in We Fight Fraud's own investigations. REPORTING FRAUD: If you suspect fraud, report it to your bank and to Action Fraud at or if you prefer, on 0300 123 2040. If you're in Scotland, call Police Scotland on 101. About the data: Action fraud data from the NFIB dashboard shows the cost of ticket fraud for England and Wales is around £9.8m across the last 12 months. When you factor in that 86% of fraud goes unreported (Action Fraud and National Crime Agency), the more realistic figure is likely to be £70m across the last 12 months. If we regulate that with price caps, that figure will balloon to £280m (based on Bradshaw advisory research that shows level of fraud in markets with price caps is four times that of the UK). WFF's research at a Premier League football match investigation shows three in four tickets purchased were scams.
Yahoo
an hour ago
- Yahoo
Lazard Opens New UK Headquarters in Historic Manchester Square, W1
Lazard opens new, larger headquarters at 20 Manchester Square, extending the firm's near 150-year history in the UK Move reflects Lazard's continued commitment to the UK and London as one of the world's pre-eminent financial centres LONDON, June 02, 2025--(BUSINESS WIRE)--Lazard, Inc. (NYSE: LAZ) announced today that its new UK headquarters opened at 20 Manchester Square, housing both the firm's Financial Advisory and Asset Management businesses. The new, larger office reflects Lazard's commitment to London as one of the world's leading financial centres and the firm's continued growth in Europe. 20 Manchester Square will become part of Lazard's European footprint and one of its three main global offices, alongside New York and Paris. As a cornerstone of Lazard's international network, the new UK HQ extends the firm's long-standing presence in London which dates back to 1877. Cyrus Kapadia, Co-Head of European Investment Banking and CEO of UK Financial Advisory, said: "The move to 20 Manchester Square underscores our unwavering commitment to the UK and our deep-rooted heritage in London. We have been successfully growing our European teams and network to further support our clients across Europe and around the globe." Jeremy Taylor, CEO of Lazard UK Asset Management said, "20 Manchester Square is more than just a new office—it's a reflection of our values and vision. We are committed to delivering exceptional performance for our clients. This new UK headquarters embodies our dedication to innovation, collaboration, and thoughtful stewardship as we continue to best serve the needs of our clients." The new building offers modern office space and has been designed with an emphasis on innovation and sustainable standards of construction, technology and use. The space has renewable energy from solar panels on the roof and a rainwater harvesting system. The building's construction adhered to the UK Green Building Council framework for net-zero carbon emissions and recycled, long-life materials with reduced replaceability have been used across floors, walls and ceiling finishes, with water efficient taps, showers and fixtures in place throughout. 20 Manchester Square is situated next door to the Wallace Collection and Regent's Park, and the area is well known for its cultural landmarks and accessible transport links. Lazard UK is relocating from 50 Stratton Street, after over twenty years. ABOUT LAZARD Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. For more information, please visit and follow Lazard on LinkedIn. View source version on Contacts MEDIA CONTACTS Poppy Trowbridge, Financial Advisory+44 207 187 Zoe Butt, Asset Management+44 20 7448 INVESTOR CONTACT Alexandra Deignan+1 212 632 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
